Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

S Anand1

  • 1McMaster University, Hamilton General Hospital, Hamilton, Ont., Canada.

Haemostasis
|January 12, 2000
PubMed
Summary
This summary is machine-generated.

Direct thrombin inhibitors like hirudin and bivalirudin show promise for acute coronary syndromes (ACS). While hirudin is effective, it increases bleeding risk; bivalirudin may offer similar efficacy with improved safety compared to unfractionated heparin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complementary cross-gated fusion framework for brain tumor segmentation using MR images (CoGFu Net).

Journal of neuroscience methods·2026
Same author

Therapeutic Outcomes of Aloe vera Gel Compared with Triamcinolone Acetonide in Minor Aphthous Stomatitis.

Nigerian journal of clinical practice·2026
Same author

Modelling aerosol evolution under quiescent and turbulent conditions using a coupled fluid-particle dynamics solver incorporating fractal morphology.

Scientific reports·2026
Same author

Complete tumor regression with exclusive Ayurvedic treatment in adenocarcinoma of prostate: a case report.

Journal of medical case reports·2026
Same author

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same journal

Thrombosis and Haemostasis Issues in Cancer. International Conference. Bergamo, Italy, 2-4 November 2001. Lectures and abstracts.

Haemostasis·2002
Same journal

Biochemistry of cancer procoagulant.

Haemostasis·2002
Same journal

Management of thromboembolic disease in cancer patients.

Haemostasis·2002
Same journal

An overview of thromboprophylaxis in malignancy.

Haemostasis·2002
Same journal

Platelets cross-talk with tumor cells.

Haemostasis·2002
Same journal

Properties and function of heparanase in cancer metastasis and angiogenesis.

Haemostasis·2002
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Direct thrombin inhibitors present potential advantages in managing acute coronary syndromes (ACS) compared to indirect inhibitors.
  • Hirudin and bivalirudin are two direct thrombin inhibitors that have undergone clinical investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of direct thrombin inhibitors, specifically hirudin and bivalirudin, in patients with ACS.
  • To compare these agents against unfractionated heparin (UFH).

Main Methods:

  • Meta-analysis of clinical trial data from a large patient population (25,000 patients) for hirudin.
  • Meta-analysis of a smaller patient cohort for bivalirudin.

Main Results:

Related Experiment Videos

  • Hirudin demonstrated greater effectiveness than UFH in ACS treatment but was linked to a higher incidence of major bleeding.
  • Preliminary findings suggest bivalirudin may be more efficacious and safer than UFH in ACS patients.

    • Conclusions:

    • Direct thrombin inhibitors, particularly bivalirudin, warrant further investigation for ACS management due to potential efficacy and safety benefits.
    • Balancing efficacy and bleeding risk is crucial when selecting anticoagulants for ACS.